Faced with a PhI­II flop in NASH, Gilead is se­quenc­ing 15,000 pa­tients to find new drugs

Now well in­to its cam­paign to de­vel­op a new cock­tail ther­a­py for NASH — which has ini­tial­ly proved un­suc­cess­ful in its first piv­otal study — Gilead is go­ing back to the ge­net­ic draw­ing board in search of some added in­spi­ra­tion.

The big biotech has struck a deal with the Renown In­sti­tute for Health In­no­va­tion, of­fer­ing to foot the bill for their work se­quenc­ing the genes of 15,000 peo­ple with NASH and non­al­co­holic fat­ty liv­er dis­ease and com­pare them against a back­drop of 40,000 healthy peo­ple in Neva­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER